Table 1 Summary for trial design for studies included in meta-analysis.
Study | Number of participants | Intervention | Type of Stent used | Treatment durations | Primary endpoint(s) | Bleeding criteria |
|---|---|---|---|---|---|---|
RESET 20124 | 12-month group: 1058 3-month group: 1059 | 12 months clopidorgrel + aspirin vs 3 months clopidorgrel + aspirin | 3-month group: ZES 12-month group: SES, EES, ZES (early gen.) | 12 months vs 3 months | Incidence rate of cardiovascular death, MI, ST, TVR, or bleeding) at 1 year | TIMI |
EXCELLENT 20123 | 12-month group: 721 6-month group: 722 | 12 months clopidorgrel + aspirin vs 6 months clopidorgrel + aspirin | SES and EES | 12 months vs 6 months | Composite of cardiac death, MI or major bleeding during month 0–12 | TIMI |
PRODIGY 20125 | 24-month group: 987 6-month group: 983 | 24 months clopidorgrel + aspirin vs 6 months clopidorgrel + aspirin | EES (both early and new generation), PES and BMS#4 | 24 months vs 6 months | Incidence rate of death of any cause, non-fatal MI or cerebrovascular accident at month 24 | TIMI |
OPTIMIZE 20136 | 12-month group: 1563 3-month group: 1556 | 12 months clopidorgrel + aspirin vs 3 months clopidorgrel + aspirin | ZES | 12 months vs 3 months | Composite of all-cause death, MI, ST, stroke, major bleeding at month 12 | REPLACE-2, GUSTO |
DES-LATE 201410 | Continue DAPT: 2531 Discontinue DAPT: 2514 | 12 months aspirin vs 12 months aspirin + clopidogrel | SES, PES, ZES, EES and other DES | 24 months vs 12 months#1 | Composite of death due to cardiac death, MI and stroke at month 24 after randomization | TIMI |
ARCTIC-Interruption 20147 | Continue DAPT: 635 Discontinue DAPT: 641 | 12 months Thienopyridine + aspirin vs 12 months aspirin | SES, PES, ZES, EES | 18–30 months vs 12 months | Composite of all-cause mortality, MI, stroke, ST, urgent Coronary revascularization or transient ischemic attack at month 30 | STEEPLE |
SECURITY 20148 | 6-month group: 682 12-month group: 717 | 12 months aspirin + 6 months clopidogrel vs 12 months clopidogrel | ZES, EES, Nobori stent, Biomatrix stent, Promus stent | 12 months vs 6 months | Composite of cardiac death, MI, stroke, ST, type 3 or 5 bleeding as defined in the criteria at month 12 | BARC |
ISAR-SAFE 201412 | 12-month group: 2003 6-month group: 1997 | Antiplatelet drug (not specified in the presentation) + 6 months clopidogrel followed by 6 months placebo vs 12 months clopidogrel | SES, PES, ZES, EES, BES, Bioresorbable EES, BMS, drug-coated balloon and plain balloon angioplasty#3 | 12 months vs 6 months | Composite of death, MI, ST, stroke, major bleeding at month 15 | TIMI |
ITALIC 20149 | 24-month group: 910 6-month group: 912 | 24 months aspirin + 24 months vs 6 months clopidogrel, prasugrel or tricagrlor | ZES | 24 months vs 6 months#5 | Composite of death, MI, emergency TVR at month 12 | TIMI |
DAPT 201411 | 30-month group: 4710 12-month group: 4649 | 30 months aspirin + 30 months Thienopyridine vs 12 months Thienopyridine followed by 18 months placebo | SES, ZES, PES, BMS#2 | 30 months vs 12 months | No. of patients with ST and major cardiovascular and cerebrovascular events (including stroke and MI) at month 30 | BARC, GUSTO |
